Technology & innovation

This archive covers technology and innovation breakthroughs that improve lives, protect the environment, and expand human possibility. From medical devices to clean energy tools, the stories here focus on what’s working and who’s making it happen.

Holding breast cancer ribbon, for article on breast cancer recurrence blood test

New blood test can predict breast cancer return

By / / Good News For Humankind

A new blood test for breast cancer recurrence spotted returning disease an average of 15 months before symptoms or scans — and in one case, a full 41 months ahead of diagnosis. In a UK trial of 78 patients, the test correctly flagged every woman who later relapsed, scanning for 1,800 cancer-related mutations in tiny fragments of tumour DNA left circulating after treatment. Lead researcher Dr. Isaac Garcia-Murillas explained that dormant cells too few to show up on scans can trigger relapse years later — exactly the blind spot this test targets. If larger studies confirm the results, a simple blood draw could give oncologists precious extra time to act, reshaping how recurrence is caught worldwide.

A researcher handling a vaccine vial in a clinical lab for an article about cancer vaccine trials, for article on cancer chemotherapy, for article on personalized cancer vaccine

NHS launches world-first cancer vaccine matchmaking program in England

By / / Good News For Humankind

Cancer vaccine trials are now being fast-tracked through a landmark NHS program in England that matches patients with personalized mRNA vaccines built around their individual tumors. The Cancer Vaccine Launch Pad, operating across 30 hospitals, uses the same mRNA technology behind COVID-19 vaccines to design custom treatments targeting each patient’s unique cancer mutations. The program aims to eliminate remaining cancer cells after surgery before they can return. Early immune response data is encouraging, and a 2024 trial showed a 44% reduction in melanoma recurrence when similar vaccines were combined with immunotherapy.

A neuron or nerve cell is an electrically excitable cell, for article on ALS synapse-regenerating pill

Breakthrough synapse-regenerating ALS pill moves to phase 2 human trials

By / / Good News For Humankind

A once-daily ALS pill designed to rebuild neural connections — not just slow their loss — has cleared FDA approval to begin Phase 2 trials, with patients across the U.S. starting doses in April 2024. SPG302 works on synapses, the tiny junctions where neurons talk to each other, which start vanishing before motor neurons themselves die. Every ALS drug currently on the market aims to slow decline; this one is being tested for whether it can actually help recover lost function. For the roughly 30,000 Americans living with ALS, that’s a genuinely different question to be asking. If it works, it could reshape how researchers approach neurodegenerative disease far beyond ALS.

A rainforest river winding through dense green jungle in Suriname for an article about Suriname malaria-free certification, for article on dual-insecticide bed nets

New types of mosquito bed nets could cut malaria risk by up to half, trial finds

By / / Good News For Humankind

New mosquito bed nets cut malaria transmission by 20 to 50 percent in a major trial across 17 African countries, offering a real answer to the growing problem of insecticide resistance. The nets pair the standard pyrethroid coating with a second insecticide that hits mosquitoes through a different biological pathway, so the ones that used to shrug off treated nets no longer can. At under three dollars each, they cost about the same as the older versions they’re replacing. Paired with the malaria vaccine now rolling out across Africa, these nets are part of a layered defense that could meaningfully shift the trajectory of a disease that still kills hundreds of thousands of people every year.

Solar panels, for article on utility-scale solar farm, for article on Pacific renewable energy, for article on dome-shaped solar cells

Turkish scientists develop “bumpy” solar panel concept that can harvest up to 66% more energy

By / / Good News For Humankind

Dome-shaped solar cells could absorb up to 66% more light than their flat counterparts, according to new simulations from a research team at Abdullah Gül University in Türkiye. The trick is geometric: tiny hemispherical bumps catch sunlight from many angles at once, acting almost like little lenses that funnel light into the cell. That means solar power could finally work well on surfaces that flat panels struggle with, like clothing, curved windows, greenhouse roofs, and wearable medical devices. The design still needs to be built and tested in the real world, but it points toward a future where solar generation lives quietly inside the everyday surfaces around us, rather than only on dedicated rooftops.

Dentist's Hand Taking Saliva Test From Woman's Mouth, for article on handheld saliva test for breast cancer

Hand-held test for breast cancer uses your saliva and gives accurate readings in 5 seconds

By / / Good News For Humankind

A handheld breast cancer screener developed by researchers in the U.S. and Taiwan can detect cancer biomarkers from a single drop of saliva in under five seconds — using a reusable circuit board that costs just $5 and paper test strips priced in pennies. Built on the same glucose-strip technology found in home diabetes kits, the device was designed specifically for clinics and communities where mammograms and MRIs aren’t an option. Lead author Hsiao-Hsuan Wan said the goal was to make screening possible where it simply hasn’t been before. Clinical trials and approvals still lie ahead, but if it gets there, early detection — one of medicine’s most powerful tools against breast cancer — could finally reach the millions of women long left out.

A researcher examining lung cancer scans in a clinical setting for an article about mesothelioma survival rates, for article on mesothelioma survival rates

New drug quadruples three-year survival rates for mesothelioma in international trial

By / / Good News For Humankind

Mesothelioma survival rates have quadrupled over three years thanks to a drug that starves tumors of a key nutrient, marking the first successful new treatment combination for the disease in 20 years. The international ATOMIC-meso trial, led by Queen Mary University of London and published in JAMA Oncology, found that patients receiving pegargiminase alongside standard chemotherapy were significantly more likely to be alive three years later. The drug works by depleting arginine in the bloodstream, cutting off a nutrient that mesothelioma cells cannot produce themselves. For a cancer caused by asbestos exposure that has historically offered patients months rather than years, this breakthrough represents a genuine turning point.

Aerial view of container ship

Decarbonization containers turn 78% of marine emissions into limestone in new pilot

By / / Good news links

A remarkable pilot project installed on a 787-ft. container ship has proven it’s possible to capture emissions from the smokestacks of cargo ships with 78% efficiency and convert the CO2 into limestone pebbles, which can be offloaded and sold. London startup Seabound, funded by a US$1.5-million grant from the UK Government, partnered up with global shipping company Lomar to install the carbon capture equipment on one of its older and dirtier-burning ships, a medium-sized vessel capable of carrying more than 3,200 shipping containers.

Chromosomes, for article on CRISPR gene therapy hereditary angioedema

Gene therapy hailed as ‘medical magic wand’ for hereditary swelling disorder

By / / Good News For Humankind

CRISPR gene editing has freed ten patients with hereditary angioedema from the sudden, sometimes life-threatening swelling attacks that shaped their daily lives, with several remaining attack-free for 18 months and counting after a single infusion. The therapy works by switching off a gene in liver cells, stopping the painful chain reaction at its source rather than just managing symptoms. One participant who used to have attacks every three weeks has needed no medication since. Doctors are now recruiting for a phase-three trial, building on the same Nobel-winning technology that recently produced an approved cure for sickle cell disease. For a rare condition long defined by unpredictability and fear, it’s a glimpse of what gene editing could mean for millions living with inherited illness worldwide.